Consolidative Local Ablative Therapy Improves the Survival of Patients With Synchronous Oligometastatic NSCLC Harboring EGFR Activating Mutation Treated With First-Line EGFR-TKIs.

Abstract excerpt

INTRODUCTION: The aim of the current study was to investigate whether consolidative local ablative therapy (LAT) can improve the survival of patients with stage IV EGFR-mutant NSCLC who have oligometastatic disease treated with first-line EGFR-tyrosine kinase inhibitor (TKI) therapy. METHODS: Patients with stage IV EGFR-mutant NSCLC and no more than five metastases within 2 months of diagnosis were identified....

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Aged
• Share to Carcinoma, Non-Small-Cell Lung